Cargando…

Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression

BACKGROUND: Numerous studies on the prognostic significance of lysine-specific demethylase 1 (LSD1) up-regulation in tumors have different outcomes. The inconsistency originated from various studies looking into the association between LSD1 and tumor cells has prompted the decision of this quantitat...

Descripción completa

Detalles Bibliográficos
Autores principales: Agboyibor, Clement, Dong, Jianshu, Effah, Clement Y., Drokow, Emmanuel K., Pervaiz, Waqar, Li, Dié, Kang, Lei, Ma, Xinli, Li, Jian, Liu, Zhenzhen, Liu, Hong-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727833/
https://www.ncbi.nlm.nih.gov/pubmed/34802287
http://dx.doi.org/10.1177/10732748211051557
_version_ 1784626599639908352
author Agboyibor, Clement
Dong, Jianshu
Effah, Clement Y.
Drokow, Emmanuel K.
Pervaiz, Waqar
Li, Dié
Kang, Lei
Ma, Xinli
Li, Jian
Liu, Zhenzhen
Liu, Hong-Min
author_facet Agboyibor, Clement
Dong, Jianshu
Effah, Clement Y.
Drokow, Emmanuel K.
Pervaiz, Waqar
Li, Dié
Kang, Lei
Ma, Xinli
Li, Jian
Liu, Zhenzhen
Liu, Hong-Min
author_sort Agboyibor, Clement
collection PubMed
description BACKGROUND: Numerous studies on the prognostic significance of lysine-specific demethylase 1 (LSD1) up-regulation in tumors have different outcomes. The inconsistency originated from various studies looking into the association between LSD1 and tumor cells has prompted the decision of this quantitative systematic review to decipher how up-regulated LSD1 and overall survival (OS) or recurrence-free survival (RFS) or disease-free survival (DFS) are linked in tumor patients. METHODS: Articles were searched from online databases such as Embase, Web of Science Core, PubMed, Google Scholar, and Scopus. The extraction of the hazard ratios (HR) with their 95% confidence intervals (CIs) was attained and survival data of 3151 tumor patients from 17 pieces of related research were used for this meta-analysis. RESULTS: To shed light on the link between LSD1 up-regulation and the prognosis of diverse tumors, the pooled hazard ratios (HRs) with their 95% confidence intervals (CIs) were determined. In this meta-analysis, it was observed that LSD1 up-regulation is linked with poor OS (HR = 2.08, 95% CI: 1.66–2.61, P < .01) and RFS (HR = 3.09, 95% CI: 1.81–5.26, P < .01) in tumor patients. However, LSD1 up-regulation was not linked to DFS (HR = 1.49, 95% CI: .83–2.69, P = .18) in tumor patients. The subcategory examination grouped by tumor type and ethnicity showed that LSD1 up-regulation was linked with a poor outcome in the esophageal tumor and hepatocellular carcinoma and Asian patients, respectively. For clinical-pathological factors, up-regulated LSD1 was significantly linked with Lymph node status. CONCLUSION: Despite the shortfall of the present work, this meta-analysis proposes that LSD1 up-regulation may be a prognostic biomarker for patients with tumors including esophageal tumors and hepatocellular carcinoma. We propose that large-scale studies are vital to substantiate these outcomes.
format Online
Article
Text
id pubmed-8727833
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-87278332022-01-06 Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression Agboyibor, Clement Dong, Jianshu Effah, Clement Y. Drokow, Emmanuel K. Pervaiz, Waqar Li, Dié Kang, Lei Ma, Xinli Li, Jian Liu, Zhenzhen Liu, Hong-Min Cancer Control Review BACKGROUND: Numerous studies on the prognostic significance of lysine-specific demethylase 1 (LSD1) up-regulation in tumors have different outcomes. The inconsistency originated from various studies looking into the association between LSD1 and tumor cells has prompted the decision of this quantitative systematic review to decipher how up-regulated LSD1 and overall survival (OS) or recurrence-free survival (RFS) or disease-free survival (DFS) are linked in tumor patients. METHODS: Articles were searched from online databases such as Embase, Web of Science Core, PubMed, Google Scholar, and Scopus. The extraction of the hazard ratios (HR) with their 95% confidence intervals (CIs) was attained and survival data of 3151 tumor patients from 17 pieces of related research were used for this meta-analysis. RESULTS: To shed light on the link between LSD1 up-regulation and the prognosis of diverse tumors, the pooled hazard ratios (HRs) with their 95% confidence intervals (CIs) were determined. In this meta-analysis, it was observed that LSD1 up-regulation is linked with poor OS (HR = 2.08, 95% CI: 1.66–2.61, P < .01) and RFS (HR = 3.09, 95% CI: 1.81–5.26, P < .01) in tumor patients. However, LSD1 up-regulation was not linked to DFS (HR = 1.49, 95% CI: .83–2.69, P = .18) in tumor patients. The subcategory examination grouped by tumor type and ethnicity showed that LSD1 up-regulation was linked with a poor outcome in the esophageal tumor and hepatocellular carcinoma and Asian patients, respectively. For clinical-pathological factors, up-regulated LSD1 was significantly linked with Lymph node status. CONCLUSION: Despite the shortfall of the present work, this meta-analysis proposes that LSD1 up-regulation may be a prognostic biomarker for patients with tumors including esophageal tumors and hepatocellular carcinoma. We propose that large-scale studies are vital to substantiate these outcomes. SAGE Publications 2021-11-21 /pmc/articles/PMC8727833/ /pubmed/34802287 http://dx.doi.org/10.1177/10732748211051557 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Agboyibor, Clement
Dong, Jianshu
Effah, Clement Y.
Drokow, Emmanuel K.
Pervaiz, Waqar
Li, Dié
Kang, Lei
Ma, Xinli
Li, Jian
Liu, Zhenzhen
Liu, Hong-Min
Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression
title Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression
title_full Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression
title_fullStr Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression
title_full_unstemmed Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression
title_short Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression
title_sort systematic review and meta-analysis of lysine-specific demethylase 1 expression as a prognostic biomarker of cancer survival and disease progression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727833/
https://www.ncbi.nlm.nih.gov/pubmed/34802287
http://dx.doi.org/10.1177/10732748211051557
work_keys_str_mv AT agboyiborclement systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT dongjianshu systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT effahclementy systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT drokowemmanuelk systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT pervaizwaqar systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT lidie systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT kanglei systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT maxinli systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT lijian systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT liuzhenzhen systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression
AT liuhongmin systematicreviewandmetaanalysisoflysinespecificdemethylase1expressionasaprognosticbiomarkerofcancersurvivalanddiseaseprogression